Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.
暂无分享,去创建一个
C. Bombardier | C. van Durme | R. Buchbinder | D. M. van der Heijde | R. Landewé | J. Branco | U. Müller-Ladner | L. Carmona | J. Bijlsma | B. Leeb | P. Kiely | R. Burgos-Vargas | M. Østergaard | D. Elewaut | A. Catrina | C. Montecucco | D. Aletaha | L. Falzon | C. Edwards | M. Ostergaard | R. Seth | M. Wechalekar | A. Kydd | John H Y Moi | J. Zochling | M. Andrés | F. Sivera | M. Sriranganathan | O. Vinik | Irene van Echteld | A. J. Ferrari
[1] C. Bombardier,et al. Interventions for tophi in gout. , 2014, The Cochrane database of systematic reviews.
[2] R. Buchbinder,et al. Interleukin-1 inhibitors for acute gout. , 2014, The Cochrane database of systematic reviews.
[3] R. Buchbinder,et al. Intra-articular glucocorticoids for acute gout. , 2013, The Cochrane database of systematic reviews.
[4] S. Yeap,et al. Gout: why is this curable disease so seldom cured? , 2013, Annals of the rheumatic diseases.
[5] R. Buchbinder,et al. Dietary supplements for chronic gout (Protocol) , 2012 .
[6] Charles King,et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.
[7] R. Buchbinder,et al. Lifestyle interventions for chronic gout (Protocol) , 2012 .
[8] I. Reid,et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial , 2012, Annals of the rheumatic diseases.
[9] Jian-Min Yuan,et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study , 2011, Annals of the rheumatic diseases.
[10] Shuai Leng,et al. Identification of intraarticular and periarticular uric acid crystals with dual-energy CT: initial evaluation. , 2011, Radiology.
[11] M. González-Gay,et al. An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting: The Gout Evaluation and Management Study , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[12] P. Lipsky,et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. , 2011, JAMA.
[13] Y. Solak,et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[14] D. Khanna,et al. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. , 2011, Rheumatology.
[15] Y. Chiu,et al. Role of Ultrasonography in Diagnosing Gouty Arthritis , 2011 .
[16] M. Barclay,et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. , 2011, Arthritis and rheumatism.
[17] L. March,et al. Epidemiology of gout: an update. , 2010, Best practice & research. Clinical rheumatology.
[18] Sung Woo Kim,et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. , 2010, The American journal of medicine.
[19] C. van Weel,et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. , 2010, Archives of internal medicine.
[20] H. Schumacher,et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial , 2010, Arthritis research & therapy.
[21] R. Terkeltaub,et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.
[22] C. Terwee,et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study , 2010, Quality of Life Research.
[23] J. Kopec,et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study , 2010, Annals of the rheumatic diseases.
[24] R. Thiele,et al. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved , 2010, Rheumatology International.
[25] J. Singh,et al. Outcome Domains for Studies of Acute and Chronic Gout , 2009, The Journal of Rheumatology.
[26] G. Westert,et al. Effects of evidence-based clinical practice guidelines on quality of care: a systematic review , 2009, Quality and Safety in Health Care.
[27] H. Schumacher,et al. Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout , 2009, The Journal of Rheumatology.
[28] H. Schumacher,et al. Quality of Life and Disability in Patients with Treatment-Failure Gout , 2009, The Journal of Rheumatology.
[29] E. Krishnan,et al. Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter? , 2009, The Journal of Rheumatology.
[30] F. Perez-Ruiz,et al. Treating to target: a strategy to cure gout. , 2009, Rheumatology.
[31] C. McCulloch,et al. Risk factors for end-stage renal disease: 25-year follow-up. , 2009, Archives of internal medicine.
[32] H. Schumacher,et al. Clinical Diagnostic Criteria for Gout: Comparsion With the Gold Standard of Synovial Fluid Crystal Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[33] M. Fuldeore,et al. The Effect of Serum Urate on Gout Flares and Their Associated Costs: An Administrative Claims Analysis , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[34] H. Schumacher,et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.
[35] M. A. van de Laar,et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.
[36] C. Weel,et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.
[37] L. Kuller,et al. Long-term cardiovascular mortality among middle-aged men with gout. , 2008, Archives of internal medicine.
[38] I. Peláez-Ballestas,et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. , 2008, Arthritis and rheumatism.
[39] M. A. van de Laar,et al. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol , 2008, Annals of the rheumatic diseases.
[40] V. Strand,et al. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans , 2007, Annals of the rheumatic diseases.
[41] F. Perez-Ruiz,et al. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. , 2007, The Journal of rheumatology.
[42] Hyon K. Choi,et al. Independent Impact of Gout on Mortality and Risk for Coronary Heart Disease , 2007, Circulation.
[43] F. Turgut,et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions , 2007, International Urology and Nephrology.
[44] A. Hingorani,et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. , 2007, Rheumatology.
[45] R. Willburger,et al. Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout. , 2007, Rheumatology.
[46] M. Doherty,et al. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations , 2007, Annals of the rheumatic diseases.
[47] G. Gamble,et al. Computed tomography measurement of tophus volume: comparison with physical measurement. , 2007, Arthritis and rheumatism.
[48] F. Sivera,et al. Therapeutic advances in gout , 2007, Current opinion in rheumatology.
[49] P. Cameron,et al. Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial , 2007, Annals of Emergency Medicine.
[50] E. Pascual,et al. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout , 2007, Annals of the rheumatic diseases.
[51] J. Nolla,et al. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. , 2006, Arthritis and rheumatism.
[52] A. Folsom,et al. Serum uric acid and risk of ischemic stroke: the ARIC Study. , 2006, Atherosclerosis.
[53] A. Hofman,et al. Uric Acid Is a Risk Factor for Myocardial Infarction and Stroke: The Rotterdam Study , 2006, Stroke.
[54] P Netter,et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.
[55] P Netter,et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.
[56] H. Schumacher,et al. Serum Urate Levels and Gout Flares: Analysis From Managed Care Data , 2006, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[57] Jill Hayden,et al. Evaluation of the Quality of Prognosis Studies in Systematic Reviews , 2006, Annals of Internal Medicine.
[58] H. Schumacher,et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.
[59] K. Chien,et al. Hyperuricemia as a risk factor on cardiovascular events in Taiwan: The Chin-Shan Community Cardiovascular Cohort Study. , 2005, Atherosclerosis.
[60] H. Schumacher,et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. , 2005, Arthritis and rheumatism.
[61] M. Abel,et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.
[62] Taku Inoue,et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[63] J M Grimshaw,et al. Effectiveness and efficiency of guideline dissemination and implementation strategies , 2004, International Journal of Technology Assessment in Health Care.
[64] B. Cassim,et al. Hyperuricaemia and gout: clinical guideline 2003. , 2003, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[65] F. Perez-Ruiz,et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. , 2002, Arthritis and rheumatism.
[66] J. Boice,et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis , 2002, BMJ : British Medical Journal.
[67] R. Burgos-Vargas,et al. Relation between adverse events associated with allopurinol and renal function in patients with gout , 2001, Annals of the rheumatic diseases.
[68] A. Zanchetti,et al. Serum uric acid for short-term prediction of cardiovascular disease incidence in the Gubbio population Study , 2001, Acta cardiologica.
[69] K. Okada,et al. Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey , 2001, Journal of hypertension.
[70] H. Schumacher,et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? , 2001, The Journal of rheumatology.
[71] A. Folsom,et al. Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study. , 2000, Annals of epidemiology.
[72] Daniel Levy,et al. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study , 1999, Annals of Internal Medicine.
[73] F. Perez-Ruiz,et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. , 1999, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[74] D. Morgan,et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. , 1995, Annals of emergency medicine.
[75] R. Goldberg,et al. Lifestyle and biologic factors associated with atherosclerotic disease in middle-aged men. 20-year findings from the Honolulu Heart Program. , 1995, Archives of internal medicine.
[76] S. Preston,et al. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. , 1988, Arthritis and rheumatism.
[77] P. Brooks,et al. Does colchicine work? The results of the first controlled study in acute gout. , 1987, Australian and New Zealand journal of medicine.
[78] M. A. Winblad,et al. Flurbiprofen in the treatment of acute gout. A comparison with indomethacin. , 1986, The American journal of medicine.
[79] J. Scott,et al. Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis. , 1985, British journal of clinical pharmacology.
[80] U. Deesomchok,et al. Piroxicam in treatment of acute gout high dose versus low dose. , 1985, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[81] H. Rubinstein,et al. Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis. , 1979, Arthritis and rheumatism.
[82] J. Scott,et al. Multi-centre trial of naproxen and phenylbutazone in acute gout. , 1977, Advances in experimental medicine and biology.
[83] Robert G. Godfrey,et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. , 1974, Arthritis and rheumatism.
[84] C. Smyth,et al. Comparison of indomethacin and phenylbutazone in acute gout. , 1973, Annals of the rheumatic diseases.
[85] M. Thompson,et al. A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout. , 1970, Annals of physical medicine.
[86] C. Bombardier,et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative , 2012, Rheumatology.
[87] L. See,et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. , 2010, Rheumatology.
[88] K. Leung,et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[89] T. Cheng,et al. A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis. , 2004, Clinical therapeutics.
[90] T. Hosoya,et al. Combined therapy using allopurinol and benzbromarone for gout and hyperuricemia complicated with renal disorder , 1992 .
[91] A. Romanowicz,et al. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. , 1991, Current medical research and opinion.
[92] J. Levin,et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. , 1988, The Journal of rheumatology.
[93] W. Kannel,et al. Gout and coronary heart disease: the Framingham Study. , 1988, Journal of clinical epidemiology.
[94] E. Valdés. Use of tenoxicam in patients with acute gouty arthritis. , 1987, European journal of rheumatology and inflammation.
[95] K. Hande,et al. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. , 1984, The American journal of medicine.
[96] R. Eberl,et al. Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. , 1983, Arzneimittel-Forschung.
[97] C. Bombardier,et al. Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative , 2010, Annals of the rheumatic diseases.
[98] C. Bombardier,et al. Published Online First , 2007 .